SCIENMAG: Medicine & Health

DECEMBER 8, 2023

Nearly 39 million people worldwide are carriers of human immunodeficiency virus (HIV), and 1.3 million people contracted HIV in 2022[1]. Forty years after the virus was discovered at the Institut Pasteur, HIV research is still active – the aim is to elucidate the mechanisms of infection so that the virus can be eradicated.

Research 90

Research Virus 90

Drug Discovery Today

AUGUST 18, 2022

Reading, 12 August 2022. The large European interventional clinical study is investigating protection against Respiratory syncytial virus (RSV) in infants. The large European interventional clinical study is investigating protection against Respiratory syncytial virus (RSV) in infants.

Virus 100

Virus Trials Research 100

The Pharma Data

MARCH 23, 2022

To treat Ebola virus infections, researchers are taking a close look at a key piece of the virus: polymerase. Polymerase is a viral protein that directs how Ebola virus replicates its genome as it infects new hosts. Drugs that target polymerase could potentially treat Ebola virus infections and save lives.

Virus 52

Virus Small Molecule Protein Production Research 52

The Pharma Data

MAY 26, 2023

For Bolivia, a series of twelve workshops have been conducted since 2022 by the Vice Ministry of Promotion, Epidemiology and Traditional Medicine – all aimed at identifying lessons learned from COVID-19 and incorporating them into their pandemic preparedness plans.

Virus 52

Virus Vaccine Production 52

Alta Sciences

SEPTEMBER 20, 2023

AnQlar is a nanoparticle intended to help prevent the spread of negatively charged viruses such as COVID-19 and influenza via intranasal spray, and has been shown to inhibit the ability of the virus to replicate at non-toxic concentrations. We look forward to further collaboration with Virpax in the near-future.”

Virus 40

Virus Clinical Pharmacology Drugs FDA Approval 40

The Pharma Data

MAY 5, 2022

In animal studies that mimic human exposures, an investigational COVID vaccine designed to be taken orally not only protects the host, but also decreases the airborne spread of the virus to other close contacts. Because of this, they did not shed as much virus through normal airborne exposures. Science Translational Medicine, 2022.

Vaccine 52

Vaccine Disease Virus Science 52

Codon

OCTOBER 13, 2024

Through genetic engineering, researchers have developed Golden Rice which can help address the problem of vitamin A deficiency , cotton that produces its own insecticide , virus-resistant papayas , and more. Yields were devastated. These ringspot-resistant papayas entered production in 1998 and resuscitated the industry.

Engineering 108

Engineering Virus Production DNA 108

Drug Target Review

OCTOBER 25, 2023

2015 March 3 [2022 December 15]; 2015(8):7-12. A human foetus contains genetic material from both parents, which makes it partly foreign to the pregnant person’s body. Therefore, the immune system needs to make adjustments that tolerate the developing foetus whilst protecting against harmful foreign bodies like viruses. Dovepress [Internet].

Treatment 105

Treatment Virus Research Science 105

FDA Law Blog: Drug Discovery

DECEMBER 7, 2022

Valentine — On November 22, 2022, FDA approved CSL Behring’s BLA for Hemgenix (etranacogene dezaparvovec), an AAV-based gene therapy for the treatment of adults with Hemophilia B who currently use Factor IX prophylaxis therapy, have current or historical life-threatening hemorrhage, or have repeated, serious spontaneous bleeding episodes.

Therapies 119

Therapies FDA FDA Approval Treatment 119

The Pharma Data

JANUARY 11, 2021

It also has an HIV vaccine program, with separate phase 1 trials for two vaccines planned this year, and a program to develop a vaccine against the Nipah virus, which causes a range of illnesses, including fatal encephalitis. billion doses in 2022, he said. It has already received $2.8 Martin Berman-Gorvine. Source link.

Vaccine 52

Vaccine Clinical Trials Virus RNA 52

The Pharma Data

SEPTEMBER 5, 2021

Under the agreement, AstraZeneca commits to deliver 60 million doses of the vaccine by the end of the third quarter 2021, 75 million by the end of the fourth quarter 2021 and 65 million by the end of the first quarter 2022.

Vaccine 52

Vaccine Virus Clinical Trials Trials 52

Drug Target Review

DECEMBER 7, 2023

The next stage of the investigation was to test numerous molecules such as DNA, RNA , and proteins, made by the bacterium or the virus. 2022 September 17 [2023 November 21]; 15(2022):4155-68. Predatory viruses called phages pose a great threat to bacteria, as they can infiltrate their cells to replicate and take over.

RNA 59

RNA Immune Response DNA Molecular Biology 59

The Pharma Data

APRIL 15, 2022

Designed computationally and refined in the laboratory, the new protein therapies thwarted infection by interfering with the virus’ ability to enter cells. The top protein neutralized the virus with similar or greater potency than antibody treatments with Emergency Use Authorization status from the U.S. 2022 Apr 12:eabn1252.

Treatment 52

Treatment Virus Laboratories Engineering 52

The Pharma Data

APRIL 26, 2022

A drug used to treat asthma and allergies can bind to and block a crucial protein produced by the virus SARS-CoV-2, and reduce viral replication in human immune cells, according to a new study by researchers at the Indian Institute of Science (IISc). Targeting Nsp1 could therefore reduce the damage inflicted by the virus.

Virus 52

Virus Drugs FDA Approval FDA 52

The Pharma Data

JUNE 25, 2021

The outcome confirms that only one single case was attributable to the original SARS-CoV-2 virus. “In addition, the variant-rich environment underlines the importance of developing next-generation vaccines as new virus variants continue to emerge.” More than half of the cases (57%) were caused by Variants of Concern.

Vaccine 52

Vaccine Trials Immune Response Virus 52

Common Sense for Drug Policy Blog

JULY 22, 2023

A syndemic of opioid overdose, human immunodeficiency virus (HIV), hepatitis C virus (HCV), skin and soft tissue infections (SSTI), and infective endocarditis accounts for many of the poor health outcomes among PWUH [ 2 , 3 , 4 , 5 ]. Harm Reduct J 19 , 103 (2022). dwf_admin Sat, 07/22/2023 - 12:47 Source Fitzpatrick, T.,

Virus 40

Virus Drugs 40

New Drug Approvals

JANUARY 31, 2024

BLZ945 decreases the growth of malignant cells in the mouse mammary tumor virus-driven polyomavirus middle T antigen (MMTV-PyMT) model of mammary carcinogenesis. BLZ945 attenuates the turnover rate of TAMs while increasing the number of CD8+ T cells that infiltrate cervical and breast carcinomas. twitter +919321316780 call whatsaapp EMAIL.

Small Molecule 52

Small Molecule Virus Treatment Disease 52

Agency IQ

SEPTEMBER 6, 2023

In December 2022, OPP issued two interim quantitative methods for evaluating the efficacy of antimicrobial test substances on porous surfaces. EPA solicited comments from December 2022 through February 19, 2023. Commenters also provided edits to both the virus and bacterial methods, as well as the claim and use sites.

Production 40

Production Virus Long-Term Care Facilities Laboratories 40

New Drug Approvals

SEPTEMBER 6, 2024

ACS Medicinal Chemistry Letters (2022), 13(5), 812-818 83% References Bristol-Myers Squibb: Investor Series [ Link ] Bristol-Myers Squibb: Investor Series [ Link ] MedKoo Biosciences: Afimetoran [ Link ] //////////////Afimetoran, BMS-986256, BMS 986256, WHO 11516 , phase 1 Nature Immunol., 11:373-384 (2010)). Method QC-ACN-TFA-XB.

RNA 62

RNA Clinical Trials DNA Disease 62

The Pharma Data

JUNE 1, 2022

Scientists who have long studied this molecule’s functions in bacterial infections traced development of extensive lung damage in infected mice to heightened levels of the enzyme triggered by the invading SARS-CoV-2 virus. They used a version of the SARS-CoV-2 virus that other scientists have engineered specifically to cause disease in mice.

Immune Response 52

Immune Response Virus Engineering Disease 52

The Pharma Data

DECEMBER 30, 2020

31, 2020 /PRNewswire/ — ImmVira Group Company (“the Company”), a biotechnology platform dedicated to the development of oncolytic virus(“OV”) and vector type approaches to create more effective and safer therapies against cancer, announced today the signing of Series C financing.

Virus 40

Virus International Trials Clinical Trials 40

The Pharma Data

DECEMBER 16, 2020

NVX-CoV2373 is a protein-based vaccine candidate engineered from the genetic sequence of SARS-CoV-2, the virus that causes COVID-19 disease. is conducting late-stage clinical trials for NVX-CoV2373, its vaccine candidate against SARS-CoV-2, the virus that causes COVID-19. Additional terms of the agreement were not disclosed.

Vaccine 52

Vaccine Government Immune Response Clinical Trials 52

The Pharma Data

MAY 19, 2023

Saathvik Kannan , 17, of Columbia , Missouri , received one of two Regeneron Young Scientist Awards of $50,000 for using biocomputational methods to understand the causes of heightened infectivity in the disease mpox after it reemerged in 2022.

Engineering 52

Engineering International Science Virus 52

Drug Target Review

SEPTEMBER 25, 2024

2022 Dec 12 [cited 2024 Sep 4];22(3):213–34. Clinical evaluation of such strategies will reveal how mechanistically complementary drug combinations can help shape the future of cancer therapy. References 1.Jin Jin H, Wang L, Bernards R. Rational combinations of targeted cancer therapies: background, advances and challenges. Bell CC, Gilan O.

Small Molecule 105

Small Molecule Therapies Regulations Treatment 105

The Pharma Data

JANUARY 24, 2021

Theralase is focused on its target of enrolling and treating 11 additional patients in early 2021 for a total of 25 patients for potential Breakthrough Designation Approval and approximately 100 patients in 2021 / 2022.” ” About Theralase® Technologies Inc.

Pharmaceutical Companies 52

Pharmaceutical Companies Virus Clinical Research Pharmaceuticals 52

The Pharma Data

JUNE 22, 2023

Since the 1st of June 2022, the Long COVID Consortium, led by HUS Helsinki University Hospital, is working to elucidate the predisposing factors and mechanisms for the development of Long COVID Syndrome (LCS). The first year of the Long COVID project: What has been achieved? The lysosomes are full of digestive enzymes.

Hospitals 40

Hospitals Virus Research 40

The Pharma Data

APRIL 26, 2022

The trial will evaluate VLA15 in adults and pediatric subjects 5 years of age and above and is expected to be initiated in the third quarter of 2022, subject to regulatory approval. Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, and Pfizer Inc.

Vaccine 52

Vaccine Disease Protein Expression Trials 52

The Pharma Data

MARCH 1, 2022

New clinical data on lenacapavir were presented at the 29th Conference on Retroviruses and Opportunistic Infections (virtual CROI 2022).

FDA 52

FDA Treatment Science Therapies 52

Agency IQ

JULY 26, 2024

According to the OMUFA commitment letter , the FDA committed to the publication of a draft guidance on electronic monograph submissions by October 1, 2022, which must then be finalized by April 1, 2024. FDA-2022-D-2059 CDER NextGen portal requires an applicant to create an account and does not allow editing once submitted.

FDA 40

FDA Production Regulations Packaging 40

Agency IQ

AUGUST 18, 2023

Quick recap of accomplishments through August 2022 AgencyIQ referenced two different Commission plans. High-risk IVDs need to be tested by EURLs and the Commission released two implementing acts mid-2022 outlining the structure, tasks and fees of these labs, which set the stage for designating some changes. implementing acts on E.U.

Science 40

Science Regulations Laboratories Production 40

The Pharma Data

APRIL 11, 2023

It is designed to protect infants entering or during their first respiratory syncytial virus (RSV) season and for children up to 24 months of age who remain vulnerable to severe RSV disease through their second RSV season. 2-3 Sanofi Alliance In March 2017, AstraZeneca and Sanofi announced an agreement to develop and commercialise nirsevimab.

Disease 40

Disease Virus Science Production 40

The Pharma Data

FEBRUARY 22, 2021

Bayer plans to manufacture 160 million doses of the CureVac vaccine in 2022 as part of its cooperation agreement with CureVac N.V. Bayer AG’s decision to join forces with CureVac and help produce the vaccine is another crucial step in the fight against the virus,” said State Premier Laschet.

Vaccine 40

Vaccine Production Virus Pharmaceuticals 40

The Pharma Data

MARCH 27, 2021

Authorisation to the Board of Directors until the Annual General Meeting 2022 to allow the Company to repurchase own shares of up to 10% of the share capital subject to a holding limit of 10% of the share capital. Cancellation of Article 5.3 of the company’s Articles of Association. COVID-19 situation.

Disease 52

Disease Virus Research International 52

KIF1A

FEBRUARY 4, 2024

In addition to sequencing patients, the researchers looked for antibodies to the HTLV-1 virus in the patients’ spinal fluid. In 2022, n-Lorem worked with the Chung lab to develop an ASO to treat Susannah Rosen, A KAND superhero who has the P305L mutation in KIF1A. ASO stands for antisense oligonucleotide.

RNA 52

RNA DNA Disease Trials 52

The Pharma Data

AUGUST 12, 2020

So whereas we were expecting to have it ready at the end of 2022, we’re now hoping to have it online in 2021,” explains Matthew Duchars, chief executive of VMIC. “If you have large reservoirs of virus circulating in surrounding countries, you can’t go back to your normal trade, travel or movement of people.

Vaccine 52

Vaccine International Science Trials 52

The Pharma Data

JUNE 25, 2021

government’s confirmed order commitment to 500 million doses including 110 million doses expected to be delivered in the fourth quarter of 2021 and 90 million expected to be delivered in the first quarter of 2022. This purchase brings the U.S. As of June 14, Moderna has supplied 217 million released doses of the vaccine to the U.S.

Government 40

Government Vaccine RNA Science 40

Metabolite Tales Blog

JULY 5, 2023

Synthetic macrocycles in oncology Pactritinib is a multi-kinase JAK2/FLT3 inhibitor used for the treatment of primary and secondary myelofibrosis, approved by the FDA in 2022. Ayushi Jain and Khalid Mumtaz, 2022. CYP3A4 is involved in clearance to two major metabolites M1 and M2, representing 9.6% of parent drug exposure respectively.

Drugs 52

Drugs Metabolic Stability FDA Approval Treatment 52